Organocatalytic Asymmetric Desymmetrization of Cyclopentene-1,3-diones via Formal Diaza-ene Reaction with Donor-Acceptor Hydrazones

Subhankar Biswas,^a Subhas Chandra Pan^{*a}

Email: span@iitg.ac.in

^aDepartment of Chemistry, Indian Institute of Technology Guwahati, North Guwahati, Assam, India, 781039

Table of contents

1.	General information	S2
2.	General procedure for the synthesis of hydrazone	S 2
3.	General procedure for the synthesis of cyclopentene-1,3-dione	S 3
4.	General procedure for the synthesis of catalyst	S 4
5.	Reaction condition optimization	S 4
6.	General procedure for the synthesis of racemic products 3	S 7
7.	General procedure for the catalytic enantioselective synthesis of 3	S 7
8.	Procedure for the scale-up experiment	S 7
9.	Procedure for synthetic transformations	S 8
10.	Characterisation of the products	S10
11.	Single crystal X-ray diffraction analysis	S20
12.	NMR spectra of the products	S22
13.	HPLC chromatogram of the products	S55
14.	References	S85

1. General Information:

Chemicals and solvents were purchased from commercial suppliers and used as received. ¹H NMR spectra were recorded on 400 MHz, 500 MHz and 600 MHz spectrometer. ¹³C NMR spectra were recorded on 100 MHz, 125 MHz and 150 MHz. Chemical shifts were reported in parts per million (ppm), and the residual solvent peak was used as an internal reference: proton (CDCl₃: δ 7.260), carbon (CDCl₃: δ 77.16). Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), brs (broad singlet). Coupling constants were reported in Hertz (Hz). Using ESI mode HRMS spectra were recorded. Enantiomeric ratios were determined by HPLC analysis performed on Chiral Columns using a Daicel Chiralpak ID Column, Daicel Chiralpak IE Column, Daicel Chiralpak IF Column, and Daicel Chiralpak ADH Column. For visualizing the products UV light and I₂ were used. DCM was distilled over CaH₂ under argon and stored over 4Å molecular sieves. Silica gel (230-400 mesh size) was used for the flash column chromatography. Reactions were monitored by TLC on silica gel 60 F254 (0.25 mm).

2. General procedure for the synthesis of hydrazone (1):

Hydrazones were prepared according to previously reported procedures.^[1]



Hydrazone derivatives were prepared according to literature procedure as followed. A suspension of the corresponding hydrazine hydrochloride (10 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (10 mL) was treated with triethylamine (10 mmol, 1.0 eq.) before the corresponding aldehyde (10 mmol, 1.0 eq.) was added dropwise to the reaction mixture at 0 °C. The mixture was stirred at this temperature for 30 minutes and then for 12 h at room temperature. The crude was filtered under vacuum and the filtrates were concentrated in vacuo. The resulting solids were dissolved in dichloromethane (15 mL) and washed with HCl 1M (2 × 10 mL) and water (2 × 10 mL). The resulting organic layer was dried over Na₂SO₄ and concentrated in vacuo. The resulting solids were triturated with diethyl ether or purified by flash column chromatography to obtain the desired hydrazone.

3. General procedure for the synthesis of 2,2-disubstituted cyclopentene-1,3-dione (2):

2,2-Disubstituted cyclopentene-1,3-diones (2) were prepared according to previously reported procedures.^[2]



To a solution of **2'** (20 mmol, 1.0 equiv.) in H₂O (80 mL) was added NaOH (20 mmol, 1.0 equiv.) and TBAI (0.2 mmol, 0.01 equiv.). The mixture was stirred at room temperature for 20 min. Then R²Br (30 mmol, 1.5 equiv.) was added. The reaction mixture was stirred at 50 °C for 24 h and then cooled to room temperature. The reaction mixture was extracted with EtOAc (3 x 40 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography on silica gel to afford target compounds.

To a solution of **2**" (2.41 g, 11.92 mmol, 1.0 equiv.) in 86 mL of MeOH was added copper(II) bromide (5.86 g, 26.22 mmol, 2.2 equiv.) and the resulting brown solution was stirred at 90 °C under argon atmosphere. After 1 h the reaction mixture was cooled to r.t., quenched with 20 mL of distilled water followed by 20 mL of 1 M aq. HCl solution, 50 mL of Et2O was added and the organic phase was separated from aqueous phase. Aqueous phase was back-extracted with Et2O (2×20 mL). The combined organic phase was dried over anh. MgSO4 and concentrated under reduced pressure. The crude reaction mixture was purified by silica-gel column chromatography (10% EtOAc in petroleum ether) to obtain a yellow crystalline solid.

4. General procedure for the synthesis of catalyst:

The catalyst (I - VII) was prepared according to reported procedures.^[3]

5. Reaction condition optimization:

Table S1: Optimization of catalyst^a



entry ^[a]	cat.	yield ^[b]	dr ^[c]	er ^[d]
1.	Ι	48	7:1	69:31
2.	II	32	9:1	55:45
3.	III	36	7:1	73:27
4.	IV	52	6:1	60:40
5.	V	28	5:1	61:39
6.	VI	50	16:1	85:15
7.	VII	72	>20:1	89:11

[a] Reaction conditions: 0.075 mmol of 1a and 0.05 mmol of 2a, 10 mol% of catalyst, 0.1 (M) toluene, rt, under Ar atmosphere.
 [b] Isolated yield after flash chromatography. [c] Determined by ¹HNMR. [d] Determined by HPLC analysis.





entry ^[a]	cat.	solvent	yield ^[b]	dr ^[c]	er ^[d]
1.	VII	toluene	72	>20:1	89:11
2.	VII	CH ₂ Cl ₂	36	>20:1	79:21
3.	VII	CHCl ₃	44	>20:1	80:20
4.	VII	xylene	73	>20:1	90:10
5.	VII	mesitylene	50	>20:1	87:13
6.	VII	Benzene	38	>20:1	86:14
7.	VII	PhCF ₃	34	>20:1	84:16
8.	VII	n-hexane	18	>20:1	85:15

[a] Reaction conditions: 0.075 mmol of 1a and 0.05 mmol of 2a, 10 mol% of catalyst, 0.1 (M) solvent, rt, under Ar atmosphere.
[b] Isolated yield after flash chromatography. [c] Determined by ¹HNMR. [d] Determined by HPLC analysis.

Table S3: Optimization of additives^a



entry ^[a]	additive	yield ^[b]	dr ^[c]	er ^[d]
1.	no additive	73	>20:1	90:10
2.	$4 \mathrm{A}^{0} \mathrm{MS}$	<5	-	-
3.	Amberlite IR 120	60	>20:1	85:15
4.	Amberlyst 15	50	>20:1	86:14

[a] Reaction conditions: 0.075 mmol of **1a** and 0.05 mmol of **2a**, 10 mol% of catalyst, 0.1 (M) xylene, rt, under Ar atmosphere. [b] Isolated yield after flash chromatography. [c] Determined by ¹HNMR. [d] Determined by HPLC analysis.

Table S4: Optimization of catalyst loading^a

entry ^[a]	mol %	yield ^[b]	dr ^[c]	er ^[d]
1.	20	75	>20:1	88.5:11.5
2.	15	75	>20:1	89:11
3.	10	73	>20:1	90:10
4.	5	70	>20:1	94.5:5.5

[a] Reaction conditions: 0.075 mmol of **1a** and 0.05 mmol of **2a**, 0.1 (M) xylene, rt, under Ar atmosphere. [b] Isolated yield after flash chromatography. [c] Determined by ¹HNMR. [d] Determined by HPLC analysis.

Table S5: Optimization of solvent concentration^a



entry ^[a]	Concentration (M)	solvent	yield ^[b]	dr ^[c]	er ^[d]
1.	0.1	xylene	70	>20:1	94.5:5.5
2.	0.05	xylene	68	>20:1	95.5:4.5
3.	0.033	xylene	54	>20:1	96:4

[a] Reaction conditions: 0.075 mmol of **1a** and 0.05 mmol of **2a**, 5 mol% of catalyst, xylene, rt, under Ar atmosphere. [b] Isolated yield after flash chromatography. [c] Determined by ¹HNMR. [d] Determined by HPLC analysis.

6. General procedure for the synthesis of racemic products (*rac-3*):



In an oven dried 5 mL rb, hydrazone **1** (0.15 mmol), 2,2-disubstituted cyclopentene-1,3-dione **2** (0.1 mmol) and 20 mol% of diphenyl phosphate were taken under Ar. Then 1 mL of dry xylene was added to the reaction mixture and stirred at rt for 5 days. Progress of the reaction was monitored by TLC. After the completion of reaction, the racemic (*rac-3*) samples for HPLC analysis were obtained by preparative TLC (Merck silica-gel 60 F254 pre-coated plates of 0.25 mm thickness) using 5-10% EtOAc in petroleum ether.

7. General procedure for the catalytic enantioselective synthesis of 3:



In an oven dried 5 mL rb, hydrazone **1** (0.15 mmol), 2,2-disubstituted cyclopentene-1,3-dione **2** (0.1 mmol) and 5 mol% of catalyst **VII** were taken under Ar. Then 2 mL of dry xylene was added to the reaction mixture and stirred at rt for 5 days. Progress of the reaction was monitored by TLC. After the completion of reaction, the reaction mixture was subjected to directly in flash chromatography to obtain the product **3** (5-10% EtOAc in petroleum ether).

8. Procedure for the scale-up experiment:



In an oven dried 50 mL rb, hydrazone **1a** (333 mg, 1.5 mmol), 2,2-disubstituted cyclopentene-1,3-dione **2a** (200 mg, 1.0 mmol) and catalyst **VII** (38 mg, 5 mol%) were taken under Ar. Then 20 mL of dry xylene was added to the reaction mixture and stirred at rt for 5 days. Progress of the reaction was monitored by TLC. After the completion of reaction, the reaction mixture was subjected to directly in flash chromatography (5-10% EtOAc in petroleum ether) to obtain the product **3aa** (278 mg, 66% yield, >20:1 dr, 95:5 er).

9. Procedure for synthetic transformations:

a. Procedure for the preparation of 4:



In a screw cap vial, equipped with a magnetic stirring bar, to a solution of **3aa** (0.05 mmol) in AcOH:DCM (1:1) 1 mL was added MnO_2 (0.5 mmol, 10 equiv). The mixture was stirred at room temperature for overnight. After full conversion of **3aa**, the crude reaction mixture was directly purified by silica-gel flash column chromatography (5-10% EtOAc in petroleum ether) to obtain **4** as a yellow solid (10.9 mg, 52% yield).

b. Procedure for the preparation of 5:



In a screw cap vial, equipped with a magnetic stirring bar, to a solution of **3aa** (0.05 mmol) in 0.5 mL DCM was added DDQ (0.15 mmol, 3 eq.) and the mixture was stirred for 2 h at room temperature. After full conversion of **3aa**, the crude reaction mixture was directly purified by silica-gel flash column chromatography (5-10% EtOAc in petroleum ether) to obtain **5** as a yellow semi-solid (9.2 mg, 46% yield).

c. Procedure for the preparation of 6:



In a screw cap vial, equipped with a magnetic stirring bar, to a solution of **3aa** (0.05 mmol) in DCM (1 mL) was added CH₃NO₂ (10 equiv) and DABCO (1.5 equiv). The mixture was stirred at room temperature for 24 h. The reaction was monitored by TLC. After full conversion of **3aa**, the crude reaction mixture was directly purified by silica-gel flash column chromatography (5-10% EtOAc in petroleum ether) to obtain **6** as a yellow solid (12.5 mg, 58% yield).

d. Procedure for the preparation of 7:



In an oven dried 5 mL rb, **3ea** (0.0.05 mmol) was dissolved in 1 ml methanol/ethyl acetate (1:1), and Pd/C (10 mol %) was added. The resulting mixture was stirred at room temperature under H₂ atmosphere. The reaction was monitored by TLC. After full conversion of **3ea**, the crude reaction mixture was directly purified by silica-gel flash column chromatography (10-20% EtOAc in petroleum ether) to obtain **7** as a yellow semi-solid (13.8 mg, 68% yield).

e. Procedure for the preparation of 8:



To a round 5 ml round bottom flask, **3ae** (0.05 mmol), Pd(OAc)₂ (5 mol%), PCy₃ (5 mol%), 4methoxy phenyl boronic acid (1.5 eq.) and Na₂CO₃ (2 eq.) were added under nitrogen atomosphere. Then 0.5 ml DMF was added to the reaction mixture and the reaction mixture was stirred at room temperature for 24 h. Next H₂O was added to the mixture and the mixture was extracted with ethyl acetate. Then the combined organic layers were again washed with H₂O twice and the organic layer was dried over Na₂SO₄ and concentrated in vacuo and the crude product was purified by flash chromatography (10-20% EtOAc in petroleum ether) to obtain **8** as a yellow solid (18.6 mg, 71% yield).

10. Characterisation of the products:

Ethyl (Z)-2-((1S,3R)-3-benzyl-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3aa)



Yellow solid (28.7 mg, yield: 68%); $R_f = 0.5$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (400 MHz, Chloroform-*d*) δ 12.14 (s, 1H), 7.31 – 7.26 (m, 3H), 7.11 – 7.06 (m, 2H), 7.06 – 7.01 (m, 2H), 6.89 – 6.82 (m, 2H), 4.32 – 4.13 (m, 2H), 3.78 (s, 3H), 3.22 (dd, J = 11.4, 7.9 Hz, 1H), 2.97 (q, J = 12.8 Hz, 2H), 2.76 (dd, J = 19.0, 7.9 Hz, 1H), 2.41 (dd, J = 19.0, 11.4 Hz, 1H), 1.28 (m, 6H). ¹³C NMR (126 MHz, Chloroform-*d*) δ 216.62, 216.07, 162.43, 155.81, 136.64, 135.60, 129.79, 128.85, 127.60, 123.62, 115.34, 114.83, 61.24, 58.80, 55.73, 52.17, 44.50, 42.02,

19.88, 14.38. **ESI HRMS**: calcd. for C₂₄H₂₇N₂O₅ [M+H]⁺ 423.1914, found 423.1914. **HPLC Analysis**: er = 95.5:4.5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 17.5 min, t_{minor} = 11.1 min).

ethyl (Z)-2-((1S,3R)-3-(4-methoxybenzyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3ab)



Yellow solid (28.0 mg, yield: 62%); $R_f = 0.3$ in 2:8 ethyl acetate/hexane; dr 16:1; ¹H NMR (500 MHz, CDCl₃) δ 12.14 (s, 1H), 7.08 – 6.96 (m, 4H), 6.89 – 6.77 (m, 4H), 4.27 (dq, J = 10.1, 7.2 Hz, 1H), 4.19 (qd, J = 7.1, 3.9 Hz, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 3.27 (dd, J = 11.4, 7.7 Hz, 1H), 2.92 (q, J = 13.1 Hz, 2H), 2.75 (dd, J = 18.9, 7.8 Hz, 1H), 2.44 (dd, J = 18.9, 11.4 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.25 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 216.83, 216.30, 162.41, 158.99, 155.81, 136.66, 130.83, 127.55, 123.74, 115.35,

114.83, 114.17, 61.22, 58.91, 55.70, 55.34, 52.16, 43.79, 42.06, 19.67, 14.36. **ESI HRMS**: calcd. for C₂₅H₂₉N₂O₆ [M+H]⁺ 453.2020, found 453.2024. **HPLC Analysis**: er = 90:10, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 31.6 min, t_{minor} = 14.1 min).

ethyl (Z)-2-((1S,3R)-3-(4-fluorobenzyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3ac)



Yellow solid (24.2 mg, yield: 55%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr 7:1; ¹H NMR (600 MHz, Chloroform-*d*) δ 12.15 (s, 1H), 7.08 – 7.02 (m, 4H), 7.01 – 6.95 (m, 2H), 6.87 – 6.83 (m, 2H), 4.28 (dq, J = 10.5, 7.2 Hz, 1H), 4.19 (dq, J = 10.9, 7.1 Hz, 1H), 3.83 (s, 1H), 3.78 (s, 3H), 3.26 (dd, J = 11.2, 8.1 Hz, 1H), 3.01 – 2.89 (m, 2H), 2.81 (dd, J = 18.9, 8.1 Hz, 1H), 2.46 (dd, J = 18.9, 11.2 Hz, 1H), 1.30 – 1.26 (m, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 216.35, 215.81, 162.41, 155.87, 136.59, 131.45, 131.40, 123.41, 115.79, 115.64, 115.37, 114.85, 61.26,

58.64, 55.71, 52.18, 43.13, 41.96, 20.00, 14.38. ¹⁹F NMR (471 MHz, CDCl₃) δ -114.75. ESI HRMS: calcd. for C₂₄H₂₆FN₂O₅ [M+H]⁺ 441.1820, found 441.18221. HPLC Analysis: er =

95:5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 24.4 min, t_{minor} = 13.5 min).

ethyl (Z)-2-((1S,3R)-3-(4-chlorobenzyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3ad)



Yellow solid (29.2 mg, yield: 64%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (600 MHz, Chloroform-*d*) δ 12.17 (s, 1H), 7.30 – 7.25 (m, 2H), 7.07 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 4.30 (dt, J = 10.9, 7.1 Hz, 1H), 4.25 – 4.18 (m, 1H), 3.80 (s, 3H), 3.31 (dd, J = 11.2, 8.1 Hz, 1H), 2.99 (d, J = 13.0 Hz, 1H), 2.92 (d, J = 13.1 Hz, 1H), 2.85 (dd, J = 18.9, 8.1 Hz, 1H), 2.50 (dd, J = 18.9, 11.2 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.28 (s, 3H).

¹³C NMR (151 MHz, CDCl₃) δ 216.11, 215.59, 162.42, 155.87, 136.58, 134.19, 133.55, 131.21, 128.97, 123.34, 115.37, 114.85, 61.27, 58.52, 55.71, 52.14, 43.08, 41.93, 20.12, 14.38. **ESI HRMS**: calcd. for C₂₄H₂₆ClN₂O₅ [M+H]⁺ 457.1525, found 457.1528. **HPLC Analysis**: er = 93.5:6.5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 28.1 min, t_{minor} = 15.8 min).

ethyl (Z)-2-((1S,3R)-3-(4-bromobenzyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3ae)



Yellow solid (31.5 mg, yield: 63%); $\mathbf{R}_f = 0.6$ in 2:8 ethyl acetate/hexane; dr 12:1; ¹H NMR (600 MHz, Chloroformd) δ 12.16 (s, 1H), 7.44 – 7.39 (m, 2H), 7.07 – 7.03 (m, 2H), 6.98 – 6.93 (m, 2H), 6.87 – 6.83 (m, 2H), 4.31 – 4.25 (m, 1H), 4.20 (dq, J = 10.9, 7.1 Hz, 1H), 3.78 (s, 3H), 3.30 (dd, J = 11.2, 8.1 Hz, 1H), 2.97 – 2.87 (m, 2H), 2.84 (dd, J = 18.9, 8.1 Hz, 1H), 2.48 (dd, J = 18.9, 11.2 Hz, 1H), 1.28 (t, J = 7.2 Hz, 3H), 1.26 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 216.10, 215.58,

162.43, 155.87, 136.57, 134.69, 131.94, 131.57, 123.31, 121.68, 115.38, 114.85, 61.28, 58.46, 55.72, 52.14, 43.10, 41.93, 20.15, 14.40. **ESI HRMS**: calcd. for $C_{24}H_{26}BrN_2O_5$ [M+H]⁺ 501.1020, found 501.1025. **HPLC Analysis**: er = 94.5:5.5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 26.7 min, t_{minor} = 13.9 min).

$ethyl \quad (Z)-2-(2-(4-methoxyphenyl)hydrazineylidene)-2-((1S,3R)-3-methyl-2,4-dioxo-3-(4-(trifluoromethyl)benzyl)cyclopentyl)acetate (3af)$



Yellow solid (25.4 mg, yield: 52%); $R_f = 0.6$ in 2:8 ethyl acetate/hexane; dr 10:1; ¹H NMR (600 MHz, Chloroform-*d*) δ 12.18 (s, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 7.9 Hz, 2H), 7.08 – 7.03 (m, 2H), 6.90 – 6.84 (m, 2H), 4.29 (dd, J = 11.0, 7.1 Hz, 1H), 4.22 (dq, J = 10.9, 7.1 Hz, 1H), 3.80 (s, 3H), 3.31 (dd, J = 11.0, 8.4 Hz, 1H), 3.08 (d, J = 12.7 Hz, 1H), 3.00 (d, J = 13.0 Hz, 1H), 2.91 (dd, J = 18.9, 8.4 Hz, 1H), 2.53 (dd, J = 18.8, 11.1 Hz, 1H), 1.32 – 1.27 (m, 7H). ¹³C NMR (151

MHz, **CDCl**₃) δ 215.67, 215.12, 162.46, 155.93, 139.89, 136.56, 130.32, 125.70 (q, $J_{C-F} = 3.02$ Hz), 123.09, 117.20, 115.37, 115.09, 114.88, 61.29, 58.34, 55.72, 52.12, 42.97, 41.80, 20.34, 14.35. ¹⁹F NMR (471 MHz, CDCl₃) δ -62.56. ESI HRMS: calcd. for C₂₅H₂₅F₃N₂NaO₅

 $[M+Na]^+$ 513.1608, found 513.1610. **HPLC Analysis**: er = 95:5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 20.4 min, t_{minor} = 10.1 min).





Yellow solid (30.5 mg, yield: 70%); $R_f = 0.65$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (400 MHz, Chloroformd) δ 12.14 (s, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.10 – 7.01 (m, 3H), 6.90 – 6.82 (m, 4H), 4.32 – 4.13 (m, 2H), 3.78 (s, 3H), 3.24 (dd, J = 11.4, 7.7 Hz, 1H), 2.98 – 2.88 (m, 2H), 2.74 (dd, J = 19.0, 7.7 Hz, 1H), 2.42 (dd, J = 19.0, 11.4 Hz, 1H), 2.32 (s, 3H), 1.29 – 1.26 (m, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 216.67, 216.14, 162.41, 155.80, 138.46, 136.65, 135.47,

130.45, 128.72, 128.34, 126.80, 123.71, 115.32, 114.83, 61.23, 58.83, 55.71, 52.21, 44.57, 42.07, 21.49, 19.78, 14.37. **ESI HRMS**: calcd. for C₂₅H₂₉N₂O₅ [M+H]⁺ 437.2071, found 437.2071. **HPLC Analysis**: er = 95:5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 16.8 min, t_{minor} = 10.7 min).

ethyl (Z)-2-((1S,3R)-3-(3-chlorobenzyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3ah)



Yellow solid (26.9 mg, yield: 59%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr 7:1; ¹H NMR (600 MHz, Chloroform-*d*) δ 12.16 (s, 1H), 7.26 – 7.21 (m, 2H), 7.08 (q, J = 2.0 Hz, 1H), 7.05 (dd, J = 8.8, 2.0 Hz, 2H), 6.99 – 6.94 (m, 1H), 6.87 – 6.83 (m, 2H), 4.29 (tt, J = 8.4, 5.3 Hz, 1H), 4.21 (dq, J = 10.8, 7.1 Hz, 1H), 3.83 (s, 1H), 3.78 (s, 3H), 3.34 (dd, J = 11.2, 8.3 Hz, 1H), 3.00 – 2.89 (m, 2H), 2.87 (dd, J = 18.9, 8.2 Hz, 1H), 2.51 (dd, J = 18.9, 11.2 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.27 (s,

3H). ¹³C NMR (151 MHz, CDCl₃) δ 215.89, 215.35, 162.50, 155.88, 137.71, 136.62, 134.62, 130.07, 129.88, 128.11, 127.84, 123.27, 115.38, 114.87, 61.30, 58.42, 55.73, 52.09, 43.22, 41.79, 20.12, 14.41. ESI HRMS: calcd. for C₂₄H₂₆ClN₂O₅ [M+H]⁺ 457.1525, found 457.1526. HPLC Analysis: er = 94:6, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 32.3 min, t_{minor} = 21.7 min).

ethyl (Z)-2-((1S,3R)-3-(3-bromobenzyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3ai)



Yellow solid (30.5 mg, yield: 61%); $R_f = 0.6$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (600 MHz, Chloroformd) δ 12.16 (s, 1H), 7.41 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.24 (d, J = 1.9 Hz, 1H), 7.17 (t, J = 7.8 Hz, 1H), 7.07 – 7.03 (m, 2H), 7.02 (dt, J = 7.8, 1.4 Hz, 1H), 6.88 – 6.83 (m, 2H), 4.25 (ddq, J = 50.3, 10.9, 7.1 Hz, 2H), 3.78 (s, 3H), 3.34 (dd, J = 11.2, 8.3 Hz, 1H), 2.98 – 2.88 (m, 2H), 2.88 – 2.83 (m, 1H), 2.52 (dd, J = 18.9, 11.2 Hz, 1H), 1.29 (t, J = 7.2 Hz, 3H), 1.27

(s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 215.90, 215.36, 162.49, 155.88, 138.00, 136.62, 132.77, 130.79, 130.35, 128.59, 123.28, 122.82, 115.39, 114.86, 61.32, 58.44, 55.74, 52.12, 43.15, 41.81, 20.12, 14.43. ESI HRMS: C₂₄H₂₆BrN₂O₅ [M+H]⁺ 501.1020, found 501.1022.

HPLC Analysis: er = 95:5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 22.9 min, t_{minor} = 16.2 min).

ethyl (Z)-2-((1S,3R)-3-(2-fluorobenzyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3aj)



Yellow solid (25.5 mg, yield: 58%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (500 MHz, Chloroform-*d*) δ 12.16 (s, 1H), 7.30 – 7.24 (m, 1H), 7.16 – 6.98 (m, 5H), 6.88 – 6.82 (m, 2H), 4.26 (dq, J = 10.9, 7.2 Hz, 1H), 4.17 (dq, J = 10.9, 7.1 Hz, 1H), 3.84 – 3.75 (m, 4H), 2.98 (s, 2H), 2.92 (dd, J = 19.0, 11.5 Hz, 1H), 2.82 (dd, J = 19.0, 7.5 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.23 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 214.76, 214.41, 162.35, 161.96 (d, $J_{C-F} = 247.64$ Hz), 155.83, 136.65,

132.42 (d, $J_{C-F} = 3.02$ Hz), 129.67 (d, $J_{C-F} = 9.06$ Hz), 124.33 (d, $J_{C-F} = 4.53$ Hz), 123.84, 122.23 (d, $J_{C-F} = 16.61$ Hz), 115.80 (d, $J_{C-F} = 22.65$ Hz), 115.40, 114.83, 61.30, 57.69, 55.72, 51.39, 41.50, 36.26 (d, $J_{C-F} = 3.02$ Hz), 17.84, 14.30. ¹⁹F NMR (471 MHz, CDCl₃) δ -114.75. ESI HRMS: calcd. for C₂₄H₂₆FN₂O₅ [M+H]⁺ 441.1820, found 441.18223. HPLC Analysis: er = 95:5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 21.0 min, t_{minor} = 16.8 min).

ethyl (Z)-2-((1S,3R)-3-(2-chlorobenzyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3ak)



Yellow solid (31.0 mg, yield: 68%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (600 MHz, Chloroform-*d*) δ 12.16 (s, 1H), 7.41 – 7.35 (m, 1H), 7.25 – 7.19 (m, 2H), 7.19 – 7.13 (m, 1H), 7.10 – 7.04 (m, 2H), 6.88 – 6.82 (m, 2H), 4.26 (dq, J = 10.8, 7.2 Hz, 1H), 4.17 (dq, J = 10.8, 7.1 Hz, 1H), 3.83 – 3.79 (m, 1H), 3.78 (s, 3H), 3.18 – 3.10 (m, 2H), 2.91 (dd, J = 19.0, 11.7 Hz, 1H), 2.82 (dd, J = 19.0, 7.4 Hz, 1H), 1.27 – 1.24 (m, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 214.89, 214.50, 162.37,

155.84, 136.67, 134.88, 133.14, 132.34, 130.08, 129.11, 126.98, 123.84, 115.41, 114.84, 61.29, 57.67, 55.73, 51.59, 41.81, 39.95, 18.18, 14.32. **ESI HRMS**: $C_{24}H_{26}CIN_2O_5 [M+H]^+ 457.1525$, found 457.1529. **HPLC Analysis**: er = 95:5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 22.5 min, t_{minor} = 18.3 min).

ethyl (Z)-2-((1S,3R)-3-(2-bromobenzyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3al)



Yellow solid (30.0 mg, yield: 60%); $R_f = 0.6$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (600 MHz, Chloroform-*d*) δ 12.16 (s, 1H), 7.57 (dd, J = 8.0, 1.3 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.20 – 7.10 (m, 2H), 7.09 – 7.05 (m, 2H), 6.87 – 6.83 (m, 2H), 4.26 (dq, J = 10.8, 7.1 Hz, 1H), 4.18 (dq, J = 10.9, 7.1 Hz, 1H), 3.83 – 3.79 (m, 1H), 3.78 (s, 3H), 3.20 – 3.14 (m, 2H), 2.92 (dd, J = 19.0, 11.7 Hz, 1H), 2.82 (dd, J = 19.0, 7.4 Hz, 1H), 1.27 – 1.24 (m, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 214.89, 214.49,

162.37, 155.85, 136.67, 134.98, 133.51, 132.16, 129.26, 127.60, 125.58, 123.83, 115.41, 114.85, 61.29, 57.67, 55.73, 51.70, 42.20, 41.93, 18.29, 14.34. **ESI HRMS**: $C_{24}H_{26}BrN_2O_5$

 $[M+H]^+$ 501.1020, found 501.1025. **HPLC Analysis**: er = 90:10, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 25.3 min, t_{minor} = 20.0 min).

ethyl (Z)-2-(2-(4-methoxyphenyl)hydrazineylidene)-2-((1S,3R)-3-methyl-3-(naphthalen-1-ylmethyl)-2,4-dioxocyclopentyl)acetate (3am)



Yellow solid (32.0 mg, yield: 68%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (600 MHz, Chloroformd) δ 12.05 (s, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.85 (dd, J = 8.0, 1.5 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.51 (dddd, J = 23.1, 8.0, 6.8, 1.3 Hz, 2H), 7.41 (dd, J = 8.2, 7.0 Hz, 1H), 7.27 (dd, J = 7.0, 5.8 Hz, 1H), 6.99 – 6.94 (m, 2H), 6.84 – 6.79 (m, 2H), 4.18 (dq, J = 10.7, 7.1 Hz, 1H), 4.09 (dq, J = 10.8, 7.1 Hz, 1H), 3.77 (s, 3H), 3.55 – 3.43 (m, 2H), 2.96 (dd, J = 11.7, 7.3 Hz,

1H), 2.58 (dd, J = 19.1, 7.4 Hz, 1H), 2.10 (dd, J = 19.1, 11.8 Hz, 1H), 1.38 (s, 3H), 1.19 (t, J = 7.1 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 216.78, 216.30, 162.28, 155.78, 136.62, 133.97, 132.00, 131.90, 128.82, 128.65, 128.53, 126.56, 126.13, 125.42, 124.20, 123.71, 115.30, 114.79, 61.15, 58.86, 55.71, 52.26, 42.27, 40.77, 19.96, 14.29. ESI HRMS: calcd. for C₂₈H₂₈N₂NaO₅ [M+Na]⁺ 495.1890, found 495.1892. HPLC Analysis: er = 96.5:3.5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 39.2 min, t_{minor} = 21.9 min).

ethyl (Z)-2-(2-(4-methoxyphenyl)hydrazineylidene)-2-((1S,3R)-3-methyl-3-(naphthalen-2-ylmethyl)-2,4-dioxocyclopentyl)acetate (3an)



Yellow solid (30.2 mg, yield: 64%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (500 MHz, Chloroformd) δ 12.11 (s, 1H), 7.88 – 7.73 (m, 3H), 7.55 (d, J = 1.8 Hz, 1H), 7.48 (td, J = 5.8, 5.3, 3.2 Hz, 2H), 7.20 (dd, J = 8.4, 1.8 Hz, 1H), 7.02 – 6.95 (m, 2H), 6.86 – 6.78 (m, 2H), 4.23 (dq, J = 10.9, 7.1 Hz, 1H), 4.14 (dq, J = 10.9, 7.1 Hz, 1H), 3.76 (s, 3H), 3.23 – 3.08 (m, 3H), 2.76 (dd, J = 18.9, 7.9 Hz, 1H), 2.37 (dd, J = 19.0, 11.3 Hz, 1H), 1.33 (s, 3H), 1.22 (t, J = 7.1

Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 216.56, 216.03, 162.42, 155.79, 136.61, 133.46, 133.21, 132.64, 128.64, 128.52, 127.99, 127.80, 127.78, 126.44, 126.17, 123.53, 115.32, 114.80, 61.19, 58.89, 55.70, 52.12, 44.50, 42.06, 20.15, 14.33. ESI HRMS: calcd. for C₂₈H₂₈N₂NaO₅ [M+Na]⁺ 495.1890, found 495.1897. HPLC Analysis: er = 95:5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 25.8 min, t_{minor} = 18.2 min).

ethyl (Z)-2-((1S,3R)-3-(benzo[d][1,3]dioxol-5-ylmethyl)-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3ao)



Yellow semi-solid (25.1 mg, yield: 54%); $R_f = 0.25$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (600 MHz, CDCl₃) δ 12.16 (s, 1H), 7.08 – 7.03 (m, 2H), 6.87 – 6.83 (m, 2H), 6.73 (d, J = 7.9 Hz, 1H), 6.58 – 6.51 (m, 2H), 5.95 (s, 2H), 4.31 – 4.25 (m, 1H), 4.19 (dq, J = 10.9, 7.1 Hz, 1H), 3.78 (s, 3H), 3.36 (dd, J = 11.3, 8.0 Hz, 1H), 2.94 – 2.84 (m, 2H), 2.81 (dd, J = 18.9, 8.0 Hz, 1H), 2.52 (dd, J = 18.9, 11.3 Hz, 1H), 1.28 (t, J = 7.2 Hz, 3H), 1.24 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ

216.58, 216.01, 162.47, 155.81, 147.82, 146.98, 136.63, 129.19, 123.54, 123.01, 115.36, 114.82, 110.15, 108.56, 101.22, 61.26, 58.81, 55.71, 52.16, 44.09, 41.98, 19.81, 14.37. **ESI HRMS**: calcd. for C₂₅H₂₇N₂O₇ [M+H]⁺ 467.1813, found 467.1818. **HPLC Analysis**: er = 92:8, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 31.3 min, t_{minor} = 19.4 min).

ethyl (Z)-2-((1S,3R)-3-cinnamyl-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3ap)



Yellow semi-solid (19.2 mg, yield: 43%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr 5:1; ¹H NMR (500 MHz, Chloroform-*d*) δ 12.20 (s, 1H), 7.36 – 7.28 (m, 5H), 7.24 (td, J = 7.0, 6.4, 3.5 Hz, 2H), 7.10 – 7.05 (m, 2H), 6.93 (d, J = 9.0 Hz, 1H), 6.88 – 6.82 (m, 2H), 6.45 (d, J = 15.7 Hz, 1H), 6.03 (dt, J = 16.1, 7.9 Hz, 1H), 4.33 – 4.24 (m, 2H), 4.24 – 4.17 (m, 1H), 3.99 (dd, J = 11.3, 7.6 Hz, 1H), 3.82 (s, 1H), 3.78 (s, 3H), 3.06 (dd, J = 18.9, 11.3 Hz, 1H), 2.91 (dd, J = 18.9, 7.6 Hz, 1H), 2.63 – 2.58 (m, 1H),

2.52 (ddd, J = 7.9, 5.3, 1.3 Hz, 2H), 1.33 (t, J = 7.1 Hz, 1H), 1.26 (t, J = 2.6 Hz, 3H), 1.24 (s, 1H), 1.23 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 215.39, 215.03, 162.40, 155.87, 136.69, 136.64, 135.15, 128.75, 127.93, 126.52, 123.83, 122.42, 115.42, 114.86, 61.34, 57.50, 55.73, 51.68, 41.74, 40.71, 18.11, 14.34. ESI HRMS: calcd. for C₂₆H₂₉N₂O₅ [M+H]⁺ 449.2071, found 449.2075. HPLC Analysis: er = 82:18, Chiralpak Phenomenex Lux C4 Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 19.2 min, t_{minor} = 15.8 min).

ethyl (Z)-2-((1S,3R)-3-allyl-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3aq)



Yellow semi-solid (21.2 mg, yield: 57%); $R_f = 0.75$ in 2:8 ethyl acetate/hexane; dr 5:1; ¹H NMR (600 MHz, Chloroform-*d*) δ 12.20 (s, 1H), 7.10 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 8.9 Hz, 2H), 5.66 (ddt, J = 17.4, 10.1, 7.5 Hz, 1H), 5.20 – 5.10 (m, 2H), 4.24 (ddq, J = 41.7, 10.8, 7.1 Hz, 2H), 3.99 (dd, J = 11.4, 7.5 Hz, 1H), 3.79 (s, 3H), 3.06 (dd, J = 19.0, 11.4 Hz, 1H), 2.90 (dd, J = 18.9, 7.5 Hz, 1H), 2.42 – 2.31 (m, 2H), 1.27 (t, J = 7.2 Hz, 3H), 1.19 (s, 3H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 215.22, 214.80,

162.37, 155.89, 136.67, 131.24, 123.92, 120.36, 115.44, 114.87, 61.33, 57.23, 55.73, 51.75, 41.67, 41.50, 17.83, 14.35. **ESI HRMS**: calcd. for $C_{20}H_{24}N_2NaO_5$ [M+Na]⁺ 395.1577, found 395.1580. **HPLC Analysis**: er = 89:11, Chiralpak Phenomenex Lux C4 Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 15.6 min, t_{minor} = 11.8 min).

ethyl (Z)-2-(2-(4-methoxyphenyl)hydrazineylidene)-2-((1S,3R)-3-methyl-2,4-dioxo-3-(prop-2-yn-1-yl)cyclopentyl)acetate (3ar)



Yellow semi-solid (18.8 mg, yield: 51%); $R_f = 0.75$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (400 MHz, Chloroform-*d*) δ 12.22 (s, 1H), 7.10 (d, J = 8.9 Hz, 2H), 6.87 (d, J = 9.0 Hz, 2H), 4.37 – 4.20 (m, 2H), 4.14 (dd, J = 11.2, 7.9 Hz, 1H), 3.79 (s, 3H), 3.16 (dd, J = 18.9, 11.2 Hz, 1H), 2.99 (dd, J = 18.9, 7.9 Hz, 1H), 2.48 (t, J = 3.0 Hz, 2H), 2.11 (t, J = 2.7 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.22 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 214.55, 214.09,

162.43, 155.93, 136.64, 123.77, 115.46, 114.89, 78.65, 71.72, 61.37, 55.75, 55.52, 52.63, 42.36, 26.12, 19.10, 14.41. **ESI HRMS**: calcd. for C₂₀H₂₃N₂O₅ [M+H]⁺ 371.1601, found 371.1606. **HPLC Analysis**: er = 89:11, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 36.4 min, t_{minor} = 27.0 min).

ethyl (Z)-2-((1S,3R)-3-benzyl-3-ethyl-2,4-dioxocyclopentyl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (3as)



Yellow semi-solid (20.4 mg, yield: 47%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr 10:1 ¹H NMR (600 MHz, Chloroform-*d*) δ 12.18 (s, 1H), 7.30 – 7.24 (m, 3H), 7.11 – 7.06 (m, 2H), 7.02 – 6.98 (m, 2H), 6.84 – 6.81 (m, 2H), 4.30 (dq, J = 10.8, 7.2 Hz, 1H), 4.21 – 4.14 (m, 1H), 3.77 (s, 3H), 3.15 – 3.04 (m, 2H), 2.97 – 2.85 (m, 2H), 2.49 (dd, J = 18.8, 10.7 Hz, 1H), 1.84 (h, J = 7.3 Hz, 2H), 1.31 (t, J = 7.2 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 216.79, 215.90, 163.16, 155.68, 136.83, 135.89, 129.87, 128.77, 127.38, 122.36, 115.14, 114.84,

63.88, 61.02, 55.72, 51.37, 42.96, 42.51, 28.74, 14.35, 9.46. **ESI HRMS**: calcd. for $C_{25}H_{28}N_2NaO_5 [M+Na]^+$ 459.1890, found 459.1892. **HPLC Analysis**: er = 90:10, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 10.8 min, t_{minor} = 7.2 min).

ethyl (Z)-2-((1S,3R)-3-benzyl-3-methyl-2,4-dioxocyclopentyl)-2-(2-phenylhydrazineylidene)acetate (3ba)



Yellow solid (20.3 mg, yield: 52%); $R_f = 0.6$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (500 MHz, Chloroform-*d*) δ 12.13 (s, 1H), 7.32 – 7.25 (m, 5H), 7.13 – 7.05 (m, 4H), 6.98 (t, *J* = 7.3 Hz, 1H), 4.24 (ddq, *J* = 46.7, 11.0, 7.2 Hz, 2H), 3.24 (dd, *J* = 11.3, 8.0 Hz, 1H), 3.04 – 2.92 (m, 2H), 2.78 (dd, *J* = 19.0, 8.0 Hz, 1H), 2.43 (dd, *J* = 19.0, 11.3 Hz, 1H), 1.30 – 1.26 (m, 6H).

¹³C NMR (126 MHz, Chloroform-*d*) δ 216.38, 215.77, 162.29, 142.76, 135.58, 129.78, 129.46, 128.84, 127.61, 124.83, 122.91, 114.14, 61.41, 58.80, 52.19, 44.47, 41.84, 19.87, 14.34. ESI HRMS: calcd. for C₂₃H₂₅N₂O₄ [M+H]⁺ 393.1809, found 393.1809. HPLC Analysis: *er* = 95:5, Chiralpak Phenomenex Lux C4 Column, n-Hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 15.0 min, t_{minor} = 17.2 min).

ethyl (Z)-2-((1S,3R)-3-benzyl-3-methyl-2,4-dioxocyclopentyl)-2-(2-(p-tolyl)hydrazineylidene)acetate (3ca)



Yellow solid (21.9 mg, yield: 54%); $R_f = 0.65$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (600 MHz, Chloroform-*d*) δ 12.11 (s, 1H), 7.32 – 7.26 (m, 3H), 7.08 (dd, J = 7.8, 1.5 Hz, 4H), 7.02 – 6.96 (m, 2H), 4.23 (ddq, J = 55.3, 10.9, 7.1 Hz, 2H), 3.24 (dd, J = 11.3, 7.9 Hz, 1H), 3.03 – 2.93 (m, 2H), 2.77 (dd, J = 19.0, 7.9 Hz, 1H), 2.42 (dd, J = 19.0, 11.3 Hz, 1H), 2.29 (s, 3H), 1.29 – 1.26 (m, 6H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 216.51,

215.93, 162.36, 140.50, 135.61, 132.46, 129.99, 129.79, 128.84, 127.60, 124.11, 114.13, 61.30, 58.80, 52.16, 44.47, 41.95, 20.87, 19.89, 14.37. **ESI HRMS**: calcd. for C₂₄H₂₇N₂O₄ [M+H]⁺ 407.1965, found 407.1966. **HPLC Analysis**: er = 89:11, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 21.8 min, t_{minor} = 13.8 min).

ethyl (Z)-2-((1S,3R)-3-benzyl-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4-isopropylphenyl)hydrazineylidene)acetate (3da)



Yellow solid (17.3 mg, yield: 40%); $R_f = 0.68$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (400 MHz, Chloroform-*d*) δ 12.12 (s, 1H), 7.30 – 7.26 (m, 3H), 7.16 – 7.13 (m, 2H), 7.08 (dd, J = 7.5, 2.1 Hz, 2H), 7.04 – 7.00 (m, 2H), 4.32 – 4.24 (m, 1H), 4.22 – 4.15 (m, 1H), 3.25 (dd, J = 11.3, 7.9 Hz, 1H), 2.97 (q, J = 12.9 Hz, 2H), 2.89 – 2.83 (m, 1H), 2.78 (dd, J = 18.9, 7.9 Hz, 1H), 2.41 (dd, J = 19.0, 11.3 Hz, 1H), 1.28 (d, J = 3.0 Hz, 6H), 1.22 (d, J = 6.9 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 216.61, 215.96,

162.38, 143.70, 140.72, 135.61, 129.79, 128.85, 127.60, 127.38, 124.10, 114.18, 61.31, 58.80, 52.12, 44.44, 41.96, 33.61, 24.21, 19.94, 14.37. **ESI HRMS**: calcd. for C₂₆H₃₀N₂NaO₄ [M+Na]⁺ 457.2098, found 457.2099. **HPLC Analysis**: er = 87.5:12.5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 21.8 min, t_{minor} = 14.0 min).

ethyl (R,Z)-2-(4-benzyl-4-methyl-3,5-dioxocyclopent-1-en-1-yl)-2-(2-(4-(benzyloxy)phenyl)hydrazineylidene)acetate (3ea)



Yellow semi-solid (21.8 mg, yield: 44%); $R_f = 0.52$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (600 MHz, CDCl₃) δ 12.16 (s, 1H), 7.47 – 7.43 (m, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.37 – 7.29 (m, 4H), 7.13 – 7.08 (m, 2H), 7.08 – 7.03 (m, 2H), 6.96 – 6.92 (m, 2H), 5.06 (s, 2H), 4.29 (dq, J = 10.9, 7.2 Hz, 1H), 4.20 (dq, J = 10.9, 7.2 Hz, 1H), 3.25 (dd, J = 11.3, 7.9 Hz, 1H), 3.05 – 2.94 (m, 2H), 2.78 (dd, J = 18.9, 7.9 Hz, 1H), 2.44 (dd, J = 18.9, 11.3 Hz, 1H), 1.31 – 1.28 (m, 6H). ¹³C NMR (151 MHz, CDCl₃) δ

216.56, 216.00, 162.41, 154.98, 137.20, 136.87, 135.60, 129.78, 128.84, 128.70, 128.08, 127.61, 127.59, 123.72, 115.98, 115.31, 70.63, 61.25, 58.80, 52.16, 44.49, 41.98, 19.87, 14.37. **ESI HRMS**: calcd. for $C_{30}H_{29}N_2O_5$ [M+H]⁺ 497.2071, found 497.2071. **HPLC Analysis**: er = 94:6, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, λ = 254 nm (t_{major} = 43.0 min, t_{minor} = 26.8 min).

ethyl (Z)-2-((1S,3R)-3-benzyl-3-methyl-2,4-dioxocyclopentyl)-2-(2-(m-tolyl)hydrazineylidene)acetate (3fa)



Yellow semi-solid (19.0 mg, yield: 47%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (500 MHz, Chloroform-*d*) δ 12.10 (s, 1H), 7.32 – 7.24 (m, 3H), 7.16 (t, J = 7.8 Hz, 1H), 7.12 – 7.05 (m, 2H), 6.95 – 6.85 (m, 2H), 6.80 (d, J = 7.6 Hz, 1H), 4.28 (dq, J = 9.3, 7.0 Hz, 1H), 4.19 (dq, J = 10.9, 7.1 Hz, 1H), 3.25 (dd, J = 11.3, 7.9 Hz, 1H), 3.03 – 2.93 (m, 2H), 2.78 (dd, J = 19.0, 7.9 Hz, 1H), 2.42 (dd, J = 18.8, 11.6 Hz, 1H), 2.33

(s, 3H), 1.29 (d, J = 7.4 Hz, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 216.53, 215.89, 162.27,

142.71, 139.43, 135.57, 129.78, 129.31, 128.86, 127.61, 124.57, 123.82, 114.76, 111.36, 61.39, 58.81, 52.21, 44.49, 41.90, 21.67, 19.85, 14.36. **ESI HRMS**: calcd. for C₂₄H₂₆N₂NaO₄ [M+Na]⁺ 429.1785, found 429.1789. **HPLC Analysis**: er = 92.5:7.5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 98/2, flow rate 1.0 mL/min, λ = 254 nm (t_{major} = 22.1 min, t_{minor} = 20.1 min).

ethyl (Z)-2-((1S,3R)-3-benzyl-3-methyl-2,4-dioxocyclopentyl)-2-(2-(naphthalen-2-yl)hydrazineylidene)acetate (3ga)



Yellow semi-solid (18.5 mg, yield: 42%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (500 MHz, CDCl₃) δ 12.33 (s, 1H), 7.79 – 7.70 (m, 3H), 7.46 – 7.40 (m, 2H), 7.38 – 7.27 (m, 5H), 7.10 (dd, J = 7.5, 2.0 Hz, 2H), 4.31 (dq, J = 10.9, 7.2 Hz, 1H), 4.22 (dq, J = 10.9, 7.1 Hz, 1H), 3.30 (dd, J = 11.4, 8.0 Hz, 1H), 3.05 – 2.94 (m, 2H), 2.82 (dd, J = 19.0, 8.0 Hz, 1H), 2.47 (dd, J = 19.0, 11.4 Hz, 1H), 1.32 – 1.27 (m, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 216.37, 215.77, 162.33, 140.45, 135.60, 134.32, 130.39, 129.82, 129.60, 128.89, 127.96, 127.65, 127.21, 126.86, 125.29, 124.34,

115.41, 109.66, 61.52, 58.85, 52.32, 44.54, 41.89, 19.87, 14.37. **ESI HRMS**: calcd. for $C_{27}H_{27}N_2O_4$ [M+H]⁺ 443.1965, found 443.1965. **HPLC Analysis**: er = 85:15, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 17.5 min, t_{minor} = 14.8 min).

ethyl (R,Z)-2-(4-benzyl-4-methyl-3,5-dioxocyclopent-1-en-1-yl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (4)



Yellow solid (10.9 mg, yield: 52%); $R_f = 0.4$ in 2:8 ethyl acetate/hexane; ¹H NMR (400 MHz, Chloroform-*d*) δ 13.03 (s, 1H), 7.38 – 7.30 (m, 2H), 7.15 – 7.07 (m, 3H), 7.06 – 6.98 (m, 3H), 6.98 – 6.90 (m, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.83 (s, 3H), 3.09 – 2.97 (m, 2H), 1.33 – 1.28 (m, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 206.35, 204.41, 163.55, 157.44, 152.71, 139.86, 136.10, 135.97, 130.00, 128.29, 126.93, 117.65, 117.10, 115.07, 61.43, 55.75, 53.37, 41.80, 19.73, 14.21. ESI HRMS: calcd. for C₂₄H₂₅N₂O₅

 $[M+H]^+$ 421.1758, found 421.1760. **HPLC Analysis**: er = 89:11, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 80/20, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 30.3 min, t_{minor} = 12.5 min).

ethyl (S)-5-benzyl-1-(4-hydroxyphenyl)-5-methyl-4,6-dioxo-1,4,5,6tetrahydrocyclopenta[c]pyrazole-3-carboxylate (5)



Yellow semi-solid (9.2 mg, yield: 46%); $\mathbf{R}_f = 0.38$ in 2:8 ethyl acetate/hexane; ¹H NMR (500 MHz, CDCl₃) δ 7.75 (d, J = 9.0 Hz, 2H), 7.08 (dq, J = 14.4, 7.1 Hz, 3H), 7.03 – 7.00 (m, 2H), 6.98 (d, J = 9.0 Hz, 2H), 6.19 (s, 1H), 4.49 (q, J = 7.2 Hz, 2H), 3.22 (d, J = 13.5 Hz, 1H), 3.11 (d, J = 13.4 Hz, 1H), 1.49 – 1.44 (m, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 190.76, 189.25, 160.10, 157.12, 150.23, 137.59, 136.30, 135.59, 130.91, 129.78, 128.51, 127.36, 123.39, 116.26, 65.61, 62.48, 42.15, 20.66, 14.32. ESI HRMS: calcd. for C₂₃H₂₁N₂O₅ [M+H]⁺ 405.1445, found 405.1446. HPLC Analysis: er = 95:5,

Chiralpak IC Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 220$ nm (t_{major} = 12.1 min, t_{minor} = 18.2 min).

ethyl (R,Z)-2-(4-benzyl-2,4-dimethyl-3,5-dioxocyclopent-1-en-1-yl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (6)



Yellow solid (12.5 mg, yield: 58%); $R_f = 0.55$ in 2:8 ethyl acetate/hexane; ¹**H NMR (400 MHz, Chloroform-***d***)** δ 12.56 (s, 1H), 7.20 – 7.07 (m, 5H), 6.99 (dd, J = 7.4, 2.1 Hz, 2H), 6.92 – 6.83 (m, 2H), 4.21 (qt, J = 7.3, 3.7 Hz, 2H), 3.80 (s, 3H), 3.02 (s, 2H), 1.94 (s, 3H), 1.29 – 1.22 (m, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 206.77, 204.19, 162.90, 156.65, 154.23, 150.69, 136.19, 129.99, 128.21, 126.89, 118.04, 116.10, 114.93, 61.11, 55.74, 52.11, 41.34, 19.84, 14.13, 10.46. ESI HRMS: calcd. for C₂₅H₂₇N₂O₅ [M+H]⁺

435.1914, found 435.1918. **HPLC Analysis**: er = 94.5:5.5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 93/7, flow rate 1.0 mL/min, λ = 220 nm (t_{major} = 21.3 min, t_{minor} = 24.0 min).

ethyl (Z)-2-((1S,3R)-3-benzyl-3-methyl-2,4-dioxocyclopentyl)-2-(2-(4hydroxyphenyl)hydrazineylidene)acetate (7)



Yellow semi-solid (13.8 mg, yield: 68%); $R_f = 0.3$ in 2:8 ethyl acetate/hexane; dr >20:1; ¹H NMR (400 MHz, Chloroform-*d*) δ 12.11 (s, 1H), 7.29 (dt, J = 7.2, 2.6 Hz, 3H), 7.13 – 7.05 (m, 2H), 7.03 – 6.94 (m, 2H), 6.85 – 6.72 (m, 2H), 4.34 – 4.14 (m, 2H), 3.22 (dd, J = 11.4, 7.9 Hz, 1H), 2.98 (q, J = 12.9 Hz, 2H), 2.75 (dd, J = 19.0, 7.9 Hz, 1H), 2.41 (dd, J = 19.0, 11.4 Hz, 1H), 1.30 – 1.26 (m, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 216.69, 216.22, 162.43,

151.70, 136.71, 135.59, 129.80, 128.87, 127.62, 123.59, 116.28, 115.52, 61.28, 58.85, 52.18, 44.52, 42.02, 19.88, 14.38. **ESI HRMS**: calcd. for C₂₃H₂₅N₂O₅ [M+H]⁺ 409.1758, found 409.1760. **HPLC Analysis**: er = 91.5:8.5, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 254$ nm (t_{major} = 19.9 min, t_{minor} = 23.4 min).

ethyl (R,Z)-2-(4-((4'-methoxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-3,5-dioxocyclopent-1-en-1-yl)-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate (8)



Yellow solid (18.6 mg, yield: 71%); $R_f = 0.3$ in 2:8 ethyl acetate/hexane; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.92 – 7.83 (m, 2H), 7.26 – 7.21 (m, 2H), 7.05 – 6.97 (m, 2H), 6.95 – 6.87 (m, 2H), 6.83 – 6.70 (m, 5H), 4.86 (s, 1H), 4.49 (q, J = 7.1 Hz, 2H), 3.87 (s, 3H), 3.76 (s, 3H), 3.16 (d, J = 13.5 Hz, 1H), 3.05 (d, J = 13.5 Hz, 1H), 1.49 – 1.40 (m, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 190.33, 188.84, 160.52, 159.81, 153.83, 150.00, 149.77, 137.95, 136.27, 134.68, 131.64, 130.99, 123.15, 121.40, 116.17, 114.95, 114.64, 65.39, 62.40, 55.92, 55.78, 40.76, 21.25,

14.33. **ESI HRMS**: calcd. for $C_{31}H_{31}N_2O_6$ [M+H]⁺ 527.2177, found 527.2180. **HPLC Analysis**: er = 94:6, Chiralpak ADH Column, n-Hexane/*i*-PrOH = 90/10, flow rate 1.0 mL/min, $\lambda = 220$ nm ($t_{major} = 43.3$ min, $t_{minor} = 26.8$ min).

11. Single crystal X-ray diffraction analysis of 3al:

CCDC No.	2405612
Empirical formula	$C_{24}H_{25}BrN_2O_5$
Formula weight	501.36
Crystal habit, colour	needle / yellow
Temperature, T	295 K
Wavelength, λ (Å)	0.71073
Crystal system	monoclinic
Space group	'P 21'
Unit cell dimensions	a = 5.5791(8) Å
	b = 31.801(4) Å
	c = 12.9476(18) Å
	$\alpha = 90^{\circ}, \beta = 90^{\circ}, \gamma = 90^{\circ}$
Volume, V (Å ³)	2297.2(5)
Z	2
Calculated density, g⋅cm ⁻³	1.450
F (000)	1032.0
Refinement method	'SHELXL-2018/3'
Goodness-of-fit on F ²	0.999
Theta(max)	25.245
Data completeness	1.96/1.00
R(reflections)	0.0747 (4457)
wR2(reflections)	0.2014 (8329)



ORTEP representation of the X-ray structure of **3al** (thermal ellipsoids at 30% probability)











zo 10 o -10 -20 -30 -40 -50 -60 -70 -80 -90 -10 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2: fl(ppm)







110 100 f1 (ppm) -10 140 130 120



20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2: f1 (ppm)













110 100 f1 (ppm) . 200 . 180 . 150 . 80 . 60 . 40






















110 100 f1 (ppm) . 140















S49











13. HPLC chromatogram of the products:





No.	Peak Name	Ret.Time (detected)	Area	Rel.Area(ident.)	Height	Amount
		min	mAU*min	%	mAU	
	11	11.08	2.205346	4.255002122	5.96611	n.a.
	2 2	17.47	49.624	95.74499788	81.998	n.a.











No.	Peak Name	Ret.Time (detected)	Area	Rel.Area(ident.)	Height Amo	ount
		min	mAU*min	%	mAU	
1	1	13.55	1.161889	4.742143532	2.87795 n.a.	
2	2 2	24.40	23.339	95.25785647	31.655 n.a.	











No.	Peak Name	Ret.Time (detected)	Area	Rel.Area(ident.)	Height Am	ount
		min	mAU*min	%	mAU	
	11	13.94	3.28822	5.576105392	8.97443 n.a.	
	2 2	26.75	55.682	94.42389461	70.055 n.a.	





No.	Peak Name	Ret.Time (detected)	Area	Rel.Area(ident.)	Height	Amoun
		min	mAU*min	%	mAU	
	11	10.16	2.441155	5.003832498	7.03666	n.a.
	2 2	20.38	46.345	94.9961675	75.521	n.a.









No.	Peak Name	Ret.Time (detected)	Area	Rel.Area(ident.)	Height Amount
		min	mAU*min	%	mAU
	11	21.68	2.279328	6.118028065	4.03882 n.a.
	2 2	32.35	34.977	93.88197193	37.192 n.a.









No.	Peak Name	Ret.Time (detected)	Area	Rel.Area(ident.)	Height	Amount
		min	mAU*min	%	mAU	
1	1	16.84	2.093752	5.188608216	4.05257	n.a.
2	2	21.06	38.259	94.81139178	63.892	n.a.







No.





No.	Peak Name	Ret.Time (detected)	Area	Rel.Area(ident.)	Height A	moun
		min	mAU*min	%	mAU	
	11	19.96	9.969988	10.19517222	15.60891 n	.a.
	2 2	25.33	87.821	89.80482778	107.720 n	.a.





No.	Peak Name	Ret.Time (detected)	Area	Rel.Area(ident.)	Height	Amount
		min	mAU*min	%	mAU	
1	1	21.93	7.548438	3.463426656	12.64327	n.a.
2	2 2	39.23	210.399	96.53657334	182.228	n.a.






































S76









i can name	1101.11110 (00100100)	nica	110		rieigin	Amoun
	min	mAU*min	%		mAU	
11	20.1	0 1.55533	3	7.439006748	2.84769	n.a.
2 2	22.0	6 19.352	2	92.56099325	27.985	n.a.

No.





Feak Maille	net. Time (detected)	Area	nel.Area(luent.)	Height	Amour
	min	mAU*min	%	mAU	
17 1	14.84	4.421706	14.83539914	12.42681	n.a.
18 2	17.50	25.383	85.16460086	55.305	n.a.

No.









No.	Peak Name	Ret.Time (detected)	Area	Rel.Area(ident.)	Height	Amount
		min	mAU*min	%	mAU	
	11	12.06	24.86157	94.60223001	30.30491	n.a.
	2 2	18.24	1.419	5.39776999	1.801	n.a.















14. References:

[1] a) M. Fernández, U. Uria, J. L. Vicario, L. Reyes, L. Carrillo, *J. Am. Chem. Soc.* 2012, **134**, 11872; b) N. Zabaleta, U. Uria, E. Reyes, L. Carrillo, J. L. Vicario, *Chem. Commun.* 2018, **54**, 8905-8908

[2] a) S. Zhou, T. Zhu, L. Zhou, C. Mou, H. Chai, Y. Lu, L. Pan, Z. Jin, Y. R. Chi, *Angew. Chem. Int. Ed.* 2019, **58**, 1784-1788; b) M. S. Manna, R. Sarkar, S. Mukherjee, *Chem.-Eur. J.* 2016, **22**, 14912. c) M. S. Manna, S. Mukherjee, *J. Am. Chem. Soc.* **2015**, *137*, 130; d) M. S. Manna, S. Mukherjee, *Chem. Sci.* 2014, **5**, 1627.

[3] S. Müller, M. J. Webber, B. List, J. Am. Chem. Soc. 2011, 133, 18534.